Artisan Global Discovery Fund’s Top Contributor: argenx SE (ARGX)

Artisan Partners, an investment management company, released its “Artisan Global Discovery Fund” second quarter investor letter. A copy of the same can be downloaded here. In the second quarter, its Investor Class: APFDX returned -20.46%, Advisor Class: APDDX posted a return of -20.42%, and Institutional Class: APHDX returned -20.40%, compared to the benchmark return of -15.66% for the MSCI All Country World Index. In addition, please check the fund’s top five holdings to know its best picks in 2022.

Artisan Partners discussed stocks like argenx SE (NASDAQ:ARGX) in the second quarter investor letter. Headquartered in Breda, the Netherlands, argenx SE (NASDAQ:ARGX) is a biotechnology company. On September 23, 2022, argenx SE (NASDAQ:ARGX) stock closed at $343.20 per share. One-month return of argenx SE (NASDAQ:ARGX) was -10.65% and its shares gained 11.43% of their value over the last 52 weeks. argenx SE (NASDAQ:ARGX) has a market capitalization of $19.626 billion.

Here is what Artisan Partners specifically said about argenx SE (NASDAQ:ARGX) in its Q2 2022 investor letter:

“argenx SE (NASDAQ:ARGX) is a commercial stage biotechnology company with an approved, first-, and potentially best-in-class therapy (FcRn) for autoimmune diseases. In its first full quarter of sales, Vyvgart meaningfully exceeded consensus sales expectations, indicating strong early market traction. In addition, it released positive phase 3 results for Vyvgart’s use in treating immune thrombocytopenia purpura, a blood disorder characterized by low platelet levels. We believe this second indication could receive FDA approval in early 2023, and the news confirms our thesis that Vyvgart is a “pipeline in a product”—a compelling new molecule which is likely to be safe and effective in numerous rare autoimmune disorders.”

Tonhom1009/Shutterstock.com

argenx SE (NASDAQ:ARGX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 35 hedge fund portfolios held argenx SE (NASDAQ:ARGX) at the end of the second quarter which was 31 in the previous quarter.

We discussed argenx SE (NASDAQ:ARGX) in another article and shared Baron Funds’ views on the company. In addition, please check out our hedge fund investor letters Q2 2022 page for more investor letters from hedge funds and other leading investors.

Disclosure: None. This article is originally published at Insider Monkey.